Myfortic Dosage/Direction for Use

Dosage regimen: The recommended dose is 720 mg twice daily (1,440 mg daily dose). In patients receiving 2 g mycophenolate mofetil (MMF), treatment can be replaced by 720 mg twice daily (1,440 mg daily dose).
General target population: Treatment should be initiated and maintained by appropriately qualified transplant specialists.
Mycophenolic acid (Myfortic) should be initiated in de-novo patients within 48 hours following transplantation.
Can be taken with or without food.
Special populations: Renal impairment: No dose adjustments are needed in patients experiencing delayed post-operative renal graft function (see PHARMACOLOGY: PHARMACOKINETICS under ACTIONS). Patients with severe chronic renal impairment <25 mL • min^-1 • 1.73 m^-2 should be carefully monitored.
Hepatic impairment: No dose adjustments are needed for renal transplant patients with severe hepatic parenchymal disease.
Pediatric patients (below 18 years): Safety and efficacy in pediatric patients have not been established. Limited pharmacokinetic data are available for pediatric renal transplant patients (see PHARMACOLOGY under ACTIONS).
Geriatric patients (65 years of age or above): No dose adjustment is required in this patient population.
Treatment during rejection episodes: Renal transplant rejection does not affect mycophenolic acid pharmacokinetics; dosage reduction or interruption of mycophenolic acid (Myfortic) is not required.
Method of administration: Mycophenolic acid (Myfortic) tablets should not be crushed in order to maintain the integrity of the enteric coating (see PHARMACOLOGY under ACTIONS and INSTRUCTIONS FOR USE AND HANDLING under CAUTIONS FOR USAGE).